You are here

VRTX

$117.42

+0.93%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 7, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-...
Sep 28, 2016
-Approximately 2,400 children ages 6 through 11 have two copies of the F508del mutation in the U.S.- - Vertex revises ORKAMBI revenue guidance for 2016 - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U....
Sep 9, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14th at 11:40 a.m. ET. Vertex will also present at The Leerink Partners Roundtable ...
Aug 15, 2016
-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation- ...
Jul 27, 2016
-Second quarter 2016 cystic fibrosis product revenues of $426 million; $245 million for ORKAMBI® (lumacaftor/ivacaftor) and $180 million for KALYDECO® (ivacaftor)- -Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 ...
Jul 14, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-...
Jul 6, 2016
-Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- -Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with pot...
Jun 10, 2016
-Real-world data presented at ECFS show long-term impact of KALYDECO across multiple measures of disease- -Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS- BASEL, Switzerland--(BUSINESS WIRE)-- Vertex Pharmaceuticals I...
May 31, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde, CA on Tuesday, June 7th at 1:40 p.m. ET (10:40 a.m. PT). Management's remarks will be access...
May 31, 2016
-Approximately 2,400 children ages 6 to 11 have two copies of the F508del mutation in the U.S.- -Target review date of September 30, 2016 set for the FDA's decision on the application- BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRT...
Apr 27, 2016
-First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO® (ivacaftor)- -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion; increases 2016 guidance for KALYDECO product re...
Apr 15, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET. To access the call, please dial (866) 501-...
Mar 10, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Barclays Healthcare Conference in Miami, FL on Tuesday, March 15th at 10:15 a.m. ET. Management's remarks will be accessible live through Vertex's website at ww...
Mar 8, 2016
-In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia- LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced tha...
Feb 24, 2016
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants, totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations. In its second yea...